Overview
The main objective of this trial was to determine the value of concurrent chemoradiotherapy for Intermediate-risk head and neck squamous cell carcinoma
Eligibility
Inclusion Criteria:
- The pathological type is head and neck squamous cell carcinoma
- Stages
- Radical surgery has been performed, and there are intermediary-risk factors (pT3/pT4, pN2/pN3, positive lymph nodes in the cervical IV/V region of oral cancer, nerve invasion, and vascular invasion).
- No evidence of distant metastasis (M0).
- Functional status: Karnofsky scale (KPS) \> 70.
- Normal bone marrow function:
- white blood cell count \> 4×109/L
- hemoglobin \> 120g/L in males, 110g/L in females
- platelet count \> 100×109/L
- Normal liver function:
- alanine aminotransferase (ALT), aspartate aminotransferase (AST) \< 1.5 times the upper limit of normal (ULN)
- alkaline phosphatase (ALP) \< 2.5×ULN
- bilirubin \< ULN.
- Normal renal function: creatinine clearance \> 60 ml/min.
- Patients must be informed of the basic contents of this study and sign informed consent.
Exclusion Criteria:
- Age \>70 years or \<18 years.
- Treatment is palliative.
- Previous chemotherapy (except induction chemotherapy prior to surgery).
- Previous radiation therapy.
- Women who are pregnant or breastfeeding
- Previous history of malignant tumor.
- With other serious medical conditions that may pose a greater risk or affect compliance with the test. Examples include:
- unstable heart disease that requires treatment
- kidney disease
- chronic hepatitis
- poorly controlled diabetes (fasting blood glucose \> 1.5×ULN)
- mental illness.
